Actively Recruiting
Antineoplastic Drugs in Elderly Patients
Led by Shandong University · Updated on 2022-07-20
500
Participants Needed
1
Research Sites
391 weeks
Total Duration
On this page
Sponsors
S
Shandong University
Lead Sponsor
Q
Qianfoshan Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose is to study the population pharmacokinetics, effectiveness and safety of antineoplastic drugs (Busulfan, Paclitaxel, Afatinib, Ceritinib, Crizotinib, Imatinib, Lapatinib, etc) in elderly patients and recommend optimized dosage regimens.
CONDITIONS
Official Title
Antineoplastic Drugs in Elderly Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 65 years or older
- Diagnosed with cancer
- Currently using antineoplastic drugs for treatment
You will not qualify if you...
- Expected to die within 48 hours
- Allergy to antineoplastic drugs
- Receiving other investigational drugs
- Considered unsuitable for inclusion by the researcher
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Shandong Provincial Qianfoshan Hospital
Jinan, Shandong, China
Actively Recruiting
Research Team
Z
Zhao Wei, Ph.D
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here